8-K
20/20 Biolabs, Inc. Announces Voting Results from Adjourned Annual Meeting for Charter Amendment
8-K
20/20 Biolabs Receives Nasdaq Deficiency Notifications Regarding Minimum Bid Price and Stockholders' Equity Requirements
8-K
AIDX Investor Update: Regulatory Progress and Commercial Growth for OneTest
8-K
20/20 Biolabs, Inc. Announces Annual Meeting Results and Adjournment of Proposal 3
8-K
20/20 BioLabs Reports Record Q2 2026 Revenue and Operational Growth
8-K
AIDX Investor Presentation: Strategic Growth, Medicare Pathway, and Operational Updates
